Cal. Code Regs. Tit. 28, § 1300.67.005 - Essential Health Benefits
CALIFORNIA ESSENTIAL HEALTH BENEFITS FILING WORKSHEET
For Individual Plan Subscriber Contracts and Evidence of Coverage ("EOC"), Small Group Plan EOCs, or Combined Individual or Small Group EOC/Disclosure Forms ("DF")
This EHB Worksheet requires plans to record how their coverage, as disclosed in EOCs, Subscriber Contracts, and DFs, complies with EHB requirements set forth in Health and Safety Code section 1367.005. The alignment of certain provisions of the Act with federal EHB categories is not meant to be legally definitive, but is offered as a way to organize required benefits as plans frequently organize them within their EOCs. Note that some benefits may be listed under multiple federal EHB categories because benefits and categories overlap in many plan EOCs. The plans must utilize the boxes in the third column to identify where the required EHB is located in plan documents and supply the necessary information to describe the benefit. For the purposes of the EHB Worksheet, "Section" refers to a provision of the Health and Safety Code and "Rule" refers to a section of Title 28 of the California Code of Regulations.
Federal Essential Health |
Required pursuant to § 1367.005(a) |
[] Individual EOC, Subscriber Contract |
Benefits Categories ("EHB") | [] Group, EOC, Subscriber Contract | |
[] Combined Individual or Group DF/EOC | ||
[] Qualified Health Plan in the Exchange | ||
[] Multi-State Plan | ||
Check all that apply. In the space below, please provide page number and section number or heading in plan documents that describe the required EHB. | ||
#1: Ambulatory Patient Services | Section 1345(b)(2) | |
Rule 1300.67(b-c) | ||
Ambulatory Care Services | ||
Section 1345(b)(1) | ||
Rule 1300.67(a) | ||
Outpatient Physician Services | ||
Section 1345(b)(4) | ||
Rule 1300.67(e) | ||
Section 1367.005(a)(2)(C) | ||
Home Health Services | ||
Section 1345(b)(2) | ||
Rule 1300.67(c) | ||
Outpatient Physical, Occupational, and Speech Therapy | ||
Section 1370.6 | ||
Cancer Clinical Trials | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(13) | ||
Other Clinical Trials | ||
Section 1373(b) | ||
Sterilization Services | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(1) | ||
Acupuncture Services | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(8) | ||
Ostomy, Urinary Supplies | ||
#2: Emergency Services | Section 1345(b)(6) | |
Rule 1300.67(g)(1) | ||
Emergency Services | ||
Section 1371.5 | ||
Rule 1300.67(g)(1) | ||
Emergency Response Ambulance Services | ||
Section 1345(b)(6) | ||
Rule 1300.67(g)(2) | ||
Out of Area Coverage and Urgently Needed Services | ||
#3: Hospitalization | Section 1345(b)(2) | |
Rule 1300.67(b-c) | ||
Inpatient Hospital Services | ||
Section 1345(b)(7) | ||
Section 1368.2 | ||
Rule 1300.67(h) | ||
Hospice Services | ||
Section 1367.635 | ||
Mastectomies and Lymph Node Dissections | ||
Section 1367.63 | ||
Reconstructive Surgery | ||
Section 1367.6 | ||
Breast Cancer Coverage, Including Surgery | ||
Section 1367.68 | ||
Jawbone Surgery | ||
Section 1367.71 | ||
Dental Anesthesia | ||
Section 1373(b) | ||
Sterilization Services | ||
Section 1374.17 | ||
Organ Transplant Services for HIV | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(2) | ||
Ambulance and Psychiatric Transport Services-Nonemergency (N2) | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(7) | ||
Organ Donation Services | ||
Benchmark Plan EHB Rule 1300.67.005(d)(10) | ||
Skilled Nursing Facility Services | ||
#4: Maternity and Newborn Care | Section 1345(b) (1-2) | |
Rule 1300.67(a-b) | ||
Inpatient Maternity Care | ||
Section 1345(b)(5) | ||
Rule 1300.67(f)(3) | ||
Prenatal Care | ||
Rule 1300.67(g)(2) | ||
Urgently Needed Services, Including Maternity Services | ||
Section 1367.62 | ||
Maternity Hospital Stay | ||
Section 1367.54 | ||
Alpha-Fetoprotein Testing | ||
Section 1373.4 | ||
Inpatient Hospital and Ambulatory Maternity Services | ||
45 CFR 147.130 | ||
HRSA Guidelines for Women's Preventive Services | ||
Breastfeeding Support, Supplies, Counseling | ||
Benchmark Plan EHB Section 1367.7 | ||
Rule 1300.67.005(d)(11): | ||
Prenatal Diagnosis of Genetic Disorders of the Fetus | ||
#5: Mental Health and Substance | Section 1345(b)(1) | |
Use Disorder Services, Including | Rule 1300.67(a) | |
Behavioral Health Treatment | Section 1374.72 | |
Section 1367.005(a)(2)(D) | ||
Mental Health Services | ||
Section 1374.73 | ||
Section 1367.005(a)(2)(D) | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(12)(A) | ||
Behavioral Health Treatment ("BHT") for PDD or Autism | ||
Benchmark Plan EHB | ||
Section 1367.005(a)(2)(D) | ||
Rule 1300.67.005(d)(6) | ||
Mental Health Services for Mental Disorders Other than SMI and SED | ||
Section 1367.005(a)(2)(D) | ||
Benchmark Plan EHB: | ||
Rule 1300.67.005(d)(3) | ||
Chemical Dependency Services | ||
#6: Prescription Drugs | Section 1367.25 | |
Coverage for Contraceptive Methods | ||
Section 1367.45 | ||
Coverage for Approved AIDS Vaccine | ||
Section 1370.6 | ||
Cancer Clinical Trials | ||
EHB Benchmark Plan Rule 1300.67.005(d)(13) | ||
Other Clinical Trials | ||
Section 1367.21 | ||
Off Label Drug Use | ||
Section 1367.002 | ||
Section 1367.06 | ||
Pediatric Asthma Services | ||
Section 1374.56 | ||
Phenylketonuria Services | ||
Section 1367.215 | ||
Pain Management Medication for Terminally Ill | ||
Section 1367.22 | ||
Coverage for Previously Approved Prescription | ||
Section 1367.24 | ||
Prescription Authorization Process for Non Formulary Drugs | ||
Rule 1300.67.24 | ||
Outpatient Prescription Drug Coverage, Limitations and Exclusions | ||
#7: Rehabilitative and Habilitative | Section 1345(b)(2) | |
Services and Devices | Rule 1300.67(c) | |
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(12) | ||
Outpatient Physical, Occupational, and Speech Therapy | ||
Section 1374.73 | ||
Section 1367.005(a)(3) | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(12)(A) | ||
Behavioral Health Treatment ("BHT") for PDD or Autism | ||
Section 1345(b)(4) | ||
Rule 1300.67(e) | ||
Section 1367.005(a)(2)(C) | ||
Home Health Services | ||
Section 1367.61 | ||
Prosthetics for Laryngectomy | ||
Section 1367.18 | ||
Orthotic and Prosthetic Devices and Services | ||
Section 1367.6 | ||
Section 1367.635 | ||
Prosthetic Devices Incident to Mastectomy | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(4) | ||
Contact Lenses to Treat Aniridia and Aphakia | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(5) | ||
Additional Durable Medical Equipment Required to be Covered | ||
Benchmark Plan EHB | ||
Rule 1300.67.005(d)(9) | ||
Additional Prosthetic-Orthotics Devices Required to be Covered | ||
#8: Laboratory Services | Section 1345(b)(3) | |
Rule 1300.67(d) | ||
Diagnostic Laboratory and Therapeutic Radiologic Services | ||
Section 1367.65 | ||
Mammography Services | ||
Section 1367.46 | ||
Rule 1300.67.24 | ||
Coverage for HIV Testing | ||
Section 1367.54 | ||
Alpha-Fetoprotein Testing | ||
Section 1367.6 | ||
Breast Cancer Screening | ||
Section 1367.64 | ||
Prostate Cancer Screening | ||
Section 1367.66 | ||
Cervical Cancer Screening | ||
Section 1367.665 | ||
Cancer Screening Tests | ||
Section 1367.67 | ||
Osteoporosis Services | ||
Section 1367.9 | ||
Diethylstilbestrol Services | ||
Benchmark Plan EHB | ||
Section 1367.7 | ||
Rule 1300.67.005(d)(11): | ||
Prenatal Diagnosis of Genetic Disorders of the Fetus | ||
#9: Preventive and Wellness | Section 1345(b)(5) | |
Services and Chronic Disease | Rule 1300.67(f) | |
Management | Section 1367.002 | |
45 CFR 147.130 | ||
75 Fed Reg 41726, 41728 | ||
HRSA Guidelines for Women's Preventive Services | ||
Preventive Health Services | ||
Section 1367.06 | ||
Pediatric Asthma Services | ||
Section 1367.35 | ||
Comprehensive Pediatric Preventive Services | ||
Section 1367.6 | ||
Breast Cancer Screening | ||
Section 1367.64 | ||
Prostate Cancer Screening | ||
Section 1367.665 | ||
General Cancer Screening | ||
Section 1367.66 | ||
Cervical Cancer Screening | ||
Section 1367.51 | ||
Diabetes Equipment and Supply Services | ||
Section 1367.65 | ||
Mammography Services | ||
Section 1367.46 | ||
Rule 1300.67.24 | ||
Coverage for HIV Testing | ||
Section 1367.67 | ||
Osteoporosis Services | ||
Section 1367.9 | ||
Diethylstilbestrol Services | ||
#10: Pediatric Services, Including | Section 1367.005(a)(5) | |
Oral and Vision Care | Benefits for pediatric oral care covered under the dental benefit received by children under the Medi-Cal program as of 2014, pursuant to the Medi-Cal Dental Program Provider Handbook in effect during the first quarter of 2014, including coverage pursuant to the Early Periodic Screening, Diagnosis, and Treatment benefit pursuant to 42 U.S.C. Section 1396 d(r), and provision of medically necessary orthodontic care provided pursuant to the federal Children's Health Insurance Program Reauthorization Act of 2009. | |
Oral Care | ||
Section 1367.005(a)(4) | ||
BCBS Association, 2014 FEP BlueVision - High Option, including but not limited to low vision benefits. | ||
Vision Care | ||
Section 1345(b)(5) | ||
Rule 1300.67(f)(4) | ||
Pediatric Vision and Hearing Services | ||
Section 1345(b)(5) | ||
Rule 1300.67(f)(5) | ||
Pediatric Immunization Services | ||
Section 1367.002 | ||
Section 1367.06 | ||
Pediatric Asthma Services | ||
Section 1367.002 | ||
Section 1367.35 | ||
Comprehensive Pediatric Preventive Services |
PRESCRIPTION DRUG BENEFITS
Directions for Plan Completion of Prescription Drug EHB-Benchmark Plan Benefits Chart
To demonstrate compliance with the prescription drug essential health benefits required under the PPACA at section 1302(b) (42 U.S.C. § 18022) and at 45 CFR § 156.122, please complete the form below indicating the number of prescription drugs offered by the Plan in each class and category of prescription drugs listed below. Plans must make whatever modifications are necessary to their current formularies so that the number of prescription drugs they cover equal or exceed the number listed in the "EHB Submission Count" column. Please attach the Plan's prescription drug list and/or formulary to this worksheet.
The plan must demonstrate it provides at least the greater of one (1) drug per category and class or the same number of drugs provided by the base-benchmark plan as indicated in the EHB Submission Count column, pursuant to 45 Code of Federal Regulations part 156.122, subparagraph (a). (78 Fed. Reg. 12834, 12867, February 25, 2013.)
CATEGORY |
CLASS |
EHB SUBMISSION COUNT | PLAN SUBMISSION COUNT |
ANALGESICS | NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | 10 | |
ANALGESICS | OPIOID ANALGESICS, LONG-ACTING | 3 | |
ANALGESICS | OPIOID ANALGESICS, SHORT-ACTING | 7 | |
ANESTHETICS | LOCAL ANESTHETICS | 2 | |
ANTI-ADDICTION/SUBSTANCE ABUSE | |||
TREATMENT AGENTS | ALCOHOL DETERRENTS/ANTI-CRAVING | 3 | |
ANTI-ADDICTION/SUBSTANCE ABUSE | |||
TREATMENT AGENTS | OPIOID DEPENDENCE TREATMENTS | 1 | |
ANTI-ADDICITION/SUBSTANCE ABUSE | |||
TREATMENT AGENTS | OPIOID REVERSAL AGENTS | 1 | |
ANTI-ADDICTION/SUBSTANCE ABUSE | |||
TREATMENT AGENTS | SMOKING CESSATION AGENTS | 0 | |
ANTI-INFLAMMATORY AGENTS | GLUCOCORTICOIDS | 20 | |
ANTI-INFLAMMATORY AGENTS | NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | 9 | |
ANTIBACTERIALS | AMINOGLYCOSIDES | 5 | |
ANTIBACTERIALS | ANTIBACTERIALS, OTHER | 14 | |
ANTIBACTERIALS | BETA-LACTAM, CEPHALOSPORINS | 7 | |
ANTIBACTERIALS | BETA-LACTAM, OTHER | 2 | |
ANTIBACTERIALS | BETA-LACTAM, PENICILLINS | 5 | |
ANTIBACTERIALS | MACROLIDES | 3 | |
ANTIBACTERIALS | QUINOLONES | 6 | |
ANTIBACTERIALS | SULFONAMIDES | 4 | |
ANTIBACTERIALS | TETRACYCLINES | 4 | |
ANTICONVULSANTS | ANTICONVULSANTS, OTHER | 3 | |
ANTICONVULSANTS | CALCIUM CHANNEL MODIFYING AGENTS | 2 | |
ANTICONVULSANTS | GAMMA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS | 3 | |
ANTICONVULSANTS | GLUTAMATE REDUCING AGENTS | 3 | |
ANTICONVULSANTS | SODIUM CHANNEL AGENTS | 4 | |
ANTIDEMENTIA AGENTS | ANTIDEMENTIA AGENTS, OTHER | 1 | |
ANTIDEMENTIA AGENTS | CHOLINESTERASE INHIBITORS | 2 | |
ANTIDEMENTIA AGENTS | N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST | 1 | |
ANTIDEPRESSANTS | ANTIDEPRESSANTS, OTHER | 6 | |
ANTIDEPRESSANTS | MONOAMINE OXIDASE INHIBITORS | 2 | |
ANTIDEPRESSANTS | SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS | 9 | |
ANTIDEPRESSANTS | TRICYCLICS | 9 | |
ANTIEMETICS | ANTIEMETICS, OTHER | 9 | |
ANTIEMETICS | EMETOGENIC THERAPY ADJUNCTS | 3 | |
ANTIFUNGALS | NO USP CLASS | 9 | |
ANTIGOUT AGENTS | NO USP CLASS | 5 | |
ANTIMIGRAINE AGENTS | ERGOT ALKALOIDS | 2 | |
ANTIMIGRAINE AGENTS | PROPHYLACTIC | 2 | |
ANTIMIGRAINE AGENTS | SEROTONIN (5-HT) 1B/1D RECEPTOR AGONISTS | 3 | |
ANTIMYASTHENIC AGENTS | PARASYMPATHOMIMETICS | 3 | |
ANTIMYCOBACTERIALS | ANTIMYCOBACTERIALS, OTHER | 2 | |
ANTIMYCOBACTERIALS | ANTITUBERCULARS | 8 | |
ANTINEOPLASTICS | ALKYLATING AGENTS | 4 | |
ANTINEOPLASTICS | ANTIANDROGENS | 3 | |
ANTINEOPLASTICS | ANTIANGIOGENIC AGENTS | 3 | |
ANTINEOPLASTICS | ANTIESTROGENS/MODIFIERS | 2 | |
ANTINEOPLASTICS | ANTIMETABOLITES | 5 | |
ANTINEOPLASTICS | ANTINEOPLASTICS, OTHER | 4 | |
ANTINEOPLASTICS | AROMATASE INHIBITORS, 3RD GENERATION | 3 | |
ANTINEOPLASTICS | ENZYME INHIBITORS | 3 | |
ANTINEOPLASTICS | MOLECULAR TARGET INHIBITORS | 13 | |
ANTINEOPLASTICS | MONOCLONAL ANTIBODIES | 0 | |
ANTINEOPLASTICS | RETINOIDS | 2 | |
ANTIPARASITICS | ANTHELMINTICS | 3 | |
ANTIPARASITICS | ANTIPROTOZOALS | 10 | |
ANTIPARASITICS | PEDICULICIDES/SCABICIDES | 2 | |
ANTIPARKINSON AGENTS | ANTICHOLINERGICS | 3 | |
ANTIPARKINSON AGENTS | ANTIPARKINSON AGENTS, OTHER | 2 | |
ANTIPARKINSON AGENTS | DOPAMINE AGONISTS | 4 | |
ANTIPARKINSON AGENTS | DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS | 2 | |
ANTIPARKINSON AGENTS | MONOAMINE OXIDASE B (MAO-B) INHIBITORS | 2 | |
ANTIPSYCHOTICS | 1ST GENERATION/TYPICAL | 10 | |
ANTIPSYCHOTICS | 2ND GENERATION/ATYPICAL | 5 | |
ANTIPSYCHOTICS | TREATMENT-RESISTANT | 1 | |
ANTISPASTICITY AGENTS | NO USP CLASS | 3 | |
ANTIVIRALS | ANTI-CYTOMEGALOVIRUS (CMV) AGENTS | 1 | |
ANTIVIRALS | ANTI-HEPATITIS B (HBV) AGENTS | 5 | |
ANTIVIRALS | ANTI-HEPATITIS C (HBC) AGENTS | 7 | |
ANTIVIRALS | ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | 5 | |
ANTIVIRALS | ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | 12 | |
ANTIVIRALS | ANTI-HIV AGENTS, INTEGRASE INHIBITORS | 2 | |
ANTIVIRALS | ANTI-HIV AGENTS, OTHER | 3 | |
ANTIVIRALS | ANTI-HIV AGENTS, PROTEASE INHIBITORS | 9 | |
ANTIVIRALS | ANTI-INFLUENZA AGENTS | 4 | |
ANTIVIRALS | ANTIHERPETIC AGENTS | 3 | |
ANXIOLYTICS | ANXIOLYTICS, OTHER | 3 | |
ANXIOLYTICS | SSRIS/SNRIS (SELECTIVE SEROTONIN REUPTAKE INHIBITORS/SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS) | 5 | |
ANXIOLYTICS | BENZODIASEPINES | 0 | |
BIPOLAR AGENTS | BIPOLAR AGENTS, OTHER | 6 | |
BIPOLAR AGENTS | MOOD STABILIZERS | 5 | |
BLOOD GLUCOSE REGULATORS | ANTIDIABETIC AGENTS | 7 | |
BLOOD GLUCOSE REGULATORS | GLYCEMIC AGENTS | 1 | |
BLOOD GLUCOSE REGULATORS | INSULINS | 6 | |
BLOOD PRODUCTS/MODIFIERS/VOLUME | |||
EXPANDERS | ANTICOAGULANTS | 3 | |
BLOOD PRODUCTS/MODIFIERS/VOLUME | |||
EXPANDERS | BLOOD FORMATION MODIFIERS | 4 | |
BLOOD PRODUCTS/MODIFIERS/VOLUME | |||
EXPANDERS | COAGULANTS | 0 | |
BLOOD PRODUCTS/MODIFIERS/VOLUME | |||
EXPANDERS | PLATELET MODIFYING AGENTS | 6 | |
CARDIOVASCULAR AGENTS | ALPHA-ADRENERGIC AGONISTS | 4 | |
CARDIOVASCULAR AGENTS | ALPHA-ADRENERGIC BLOCKING AGENTS | 4 | |
CARDIOVASCULAR AGENTS | ANGIOTENSIN II RECEPTOR ANTAGONISTS | 1 | |
CARDIOVASCULAR AGENTS | ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS | 3 | |
CARDIOVASCULAR AGENTS | ANTIARRHYTHMICS | 9 | |
CARDIOVASCULAR AGENTS | BETA-ADRENERGIC BLOCKING AGENTS | 7 | |
CARDIOVASCULAR AGENTS | CALCIUM CHANNEL BLOCKING AGENTS | 5 | |
CARDIOVASCULAR AGENTS | CARDIOVASCULAR AGENTS, OTHER | 2 | |
CARDIOVASCULAR AGENTS | DIURETICS, CARBONIC ANHYDRASE INHIBITORS | 2 | |
CARDIOVASCULAR AGENTS | DIURETICS, LOOP | 3 | |
CARDIOVASCULAR AGENTS | DIURETICS, POTASSIUM-SPARING | 2 | |
CARDIOVASCULAR AGENTS | DIURETICS, THIAZIDE | 4 | |
CARDIOVASCULAR AGENTS | DYSLIPIDEMICS, FIBRIC ACID DERIVATIVES | 2 | |
CARDIOVASCULAR AGENTS | DYSLIPIDEMICS, HMG COA REDUCTASE INHIBITORS | 4 | |
CARDIOVASCULAR AGENTS | DYSLIPIDEMICS, OTHER | 3 | |
CARDIOVASCULAR AGENTS | VASODILATORS, DIRECT-ACTING ARTERIAL | 2 | |
CARDIOVASCULAR AGENTS | VASODILATORS, DIRECT-ACTING ARTERIAL/VENOUS | 3 | |
CENTRAL NERVOUS SYSTEM AGENTS ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, AMPHETAMINES | 3 | ||
CENTRAL NERVOUS SYSTEM AGENTS ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, NON-AMPHETAMINES | 1 | ||
CENTRAL NERVOUS SYSTEM AGENTS CENTRAL NERVOUS SYSTEM AGENTS, OTHER | 2 | ||
CENTRAL NERVOUS SYSTEM AGENTS FIBROMYALGIA AGENTS | 1 | ||
CENTRAL NERVOUS SYSTEM AGENTS MULTIPLE SCLEROSIS AGENTS | 3 | ||
DENTAL AND ORAL AGENTS | NO USP CLASS | 6 | |
DERMATOLOGICAL AGENTS | NO USP CLASS | 50 | |
ENZYME REPLACEMENT/MODIFIERS | NO USP CLASS | 2 | |
GASTROINTESTINAL AGENTS ANTISPASMODICS, GASTROINTESTINAL | 2 | ||
GASTROINTESTINAL AGENTS GASTROINTESTINAL AGENTS, OTHER | 6 | ||
GASTROINTESTINAL AGENTS HISTAMINE2 (H2) RECEPTOR ANTAGONISTS | 3 | ||
GASTROINTESTINAL AGENTS IRRITABLE BOWEL SYNDROME AGENTS | 1 | ||
GASTROINTESTINAL AGENTS | LAXATIVES | 1 | |
GASTROINTESTINAL AGENTS | PROTECTANTS | 2 | |
GASTROINTESTINAL AGENTS | PROTON PUMP INHIBITORS | 2 | |
GENITOURINARY AGENTS | ANTISPASMODICS, URINARY | 2 | |
GENITOURINARY AGENTS BENIGN PROSTATIC HYPERTROPHY AGENTS | 5 | ||
GENITOURINARY AGENTS | GENITOURINARY AGENTS, OTHER | 4 | |
GENITOURINARY AGENTS | PHOSPHATE BINDERS | 2 | |
HORMONAL AGENTS, STIMULANT/ REPLACEMENT/MODIFYING (ADRENAL) NO USP CLASS | 23 | ||
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PITUITARY) NO USP CLASS | 4 | ||
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING | |||
(PROSTAGLANDINS) | NO USP CLASS | 1 | |
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING | |||
(SEX HORMONES/MODIFIERS) | ANABOLIC STEROIDS | 1 | |
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING | |||
(SEX HORMONES/MODIFIERS) | ANDROGENS | 4 | |
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING | |||
(SEX HORMONES/MODIFIERS) | ESTROGENS | 2 | |
HORMONAL AGENTS, STIMULANT/ | |||
REPLACEMENT/MODIFYING | PROGESTERONE | ||
(SEX HORMONES/MODIFIERS) | AGONISTS/ANTAGONISTS | 0 | |
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING | |||
(SEX HORMONES/MODIFIERS) | PROGESTINS | 5 | |
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING | |||
(SEX HORMONES/MODIFIERS) SELECTIVE ESTROGEN RECEPTOR | |||
MODIFYING AGENTS | 1 | ||
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID) | NO USP CLASS | 2 | |
HORMONAL AGENTS, SUPPRESSANT(ADRENAL) | NO USP CLASS | 1 | |
HORMONAL AGENTS, SUPPRESSANT(PARATHYROID) | NO USP CLASS | 2 | |
HORMONAL AGENTS, SUPPRESSANT(PITUITARY) | NO USP CLASS | 5 | |
HORMONAL AGENTS, SUPPRESSANT | |||
(THYROID) | ANTITHYROID AGENTS | 3 | |
IMMUNOLOGICAL AGENTS | ANDIOEDEMA (HAE) AGENTS | 1 | |
IMMUNOLOGICAL AGENTS | IMMUNE SUPPRESSANTS | 14 | |
IMMUNOLOGICAL AGENTS | IMMUNIZING AGENTS, PASSIVE | 0 | |
IMMUNOLOGICAL AGENTS | IMMUNOMODULATORS | 11 | |
INFLAMMATORY BOWEL DISEASE AGENTS AMINOSALICYLATES | 2 | ||
INFLAMMATORY BOWEL DISEASE AGENTS GLUCOCORTICOIDS | 5 | ||
INFLAMMATORY BOWEL DISEASE AGENTS SULFONAMIDES | 1 | ||
METABOLIC BONE DISEASE AGENTS | NO USP CLASS | 6 | |
OPHTHALMIC AGENTS | OPHTHALMIC PROSTAGLANDIN AND PROSTAMIDE ANALOGS | 2 | |
OPHTHALMIC AGENTS | OPHTHALMIC AGENTS, OTHER | 14 | |
OPHTHALMIC AGENTS | OPHTHALMIC ANTI-ALLERGY AGENTS | 2 | |
OPHTHALMIC AGENTS | OPHTHALMIC ANTI-INFLAMMATORIES | 6 | |
OPHTHALMIC AGENTS | OPHTHALMIC ANTIGLAUCOMA AGENTS | 12 | |
OTIC AGENTS | NO USP CLASS | 5 | |
RESPIRATORY TRACT | ANTI-INFLAMMATORIES, INHALED | ||
AGENTS/PULMONARY AGENTS | CORTICOSTEROIDS | 5 | |
RESPIRATORY TRACT | |||
AGENTS/PULMONARY AGENTS | ANTIHISTAMINES | 5 | |
RESPIRATORY TRACT | |||
AGENTS/PULMONARY AGENTS | ANTILEUKOTRIENES | 1 | |
RESPIRATORY TRACT | BRONCHODILATORS, | ||
AGENTS/PULMONARY AGENTS | ANTICHOLINERGIC | 2 | |
RESPIRATORY TRACT | PHOSPHDIESTERASE | ||
AGENTS/PULMONARY AGENTS | INHIBITORS, AIRWAYS DISEASE | 3 | |
RESPIRATORY TRACT | BRONCHODILATORS, | ||
AGENTS/PULMONARY AGENTS | SYMPATHOMIMETIC | 5 | |
RESPIRATORY TRACT | CYCSTIC FIBROSIS | ||
AGENTS/PULMONARY AGENTS | AGENTS | 3 | |
RESPIRATORY TRACT | |||
AGENTS/PULMONARY AGENTS | MAST CELL STABILIZERS | 1 | |
RESPIRATORY TRACT | PULMONARY | ||
AGENTS/PULMONARY AGENTS | ANTIHYPERTENSIVES | 5 | |
RESPIRATORY TRACT | RESPIRATORY | ||
AGENTS/PULMONARY AGENTS | TRACT AGENTS, OTHER | 1 | |
SKELETAL MUSCLE RELAXANTS | NO USP CLASS | 2 | |
SLEEP DISORDER AGENTS | GABA RECEPTOR MODULATORS | 1 | |
SLEEP DISORDER AGENTS | SLEEP DISORDERS, OTHER | 1 | |
THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES | ELECTROLYTE/MINERAL MODIFIERS | 4 | |
THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES | ELECTROLYTE/MINERAL REPLACEMENT | 3 | |
THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES | VITAMINS | 0 |
Notes
2. New section refiled 12-16-2013 as an emergency, including amendment of subsection (c)(4) and subsection (g) -- worksheet; operative 1-2-2014 (Register 2013, No. 51). A Certificate of Compliance must be transmitted to OAL by 4-2-2014 or emergency language will be repealed by operation of law on the following day.
3. Editorial correction restoring inadvertently deleted portions of Filing Worksheet (Register 2014, No. 16).
4. Certificate of Compliance as to 12-16-2013 order transmitted to OAL 3-4-2014 and filed 4-14-2014 (Register 2014, No. 16).
5. Amendment filed 11-28-2016 as an emergency; operative 11-28-2016 (Register 2016, No. 49). A Certificate of Compliance must be transmitted to OAL by 5-30-2017 or emergency language will be repealed by operation of law on the following day.
6. Certificate of Compliance as to 11-28-2016 order transmitted to OAL 5-16-2017 and filed 6-27-2017 (Register 2017, No. 26).
Note: Authority cited: Sections 1341, 1344, 1346 and 1367.005, Health and Safety Code. Reference: Section 1367.005, Health and Safety Code.
2. New section refiled 12-16-2013 as an emergency, including amendment of subsection (c)(4) and subsection (g) - worksheet; operative 1-2-2014 (Register 2013, No. 51). A Certificate of Compliance must be transmitted to OAL by 4-2-2014 or emergency language will be repealed by operation of law on the following day.
3. Editorial correction restoring inadvertently deleted portions of Filing Worksheet (Register 2014, No. 16).
4. Certificate of Compliance as to 12-16-2013 order transmitted to OAL 3-4-2014 and filed 4-14-2014 (Register 2014, No. 16).
5. Amendment filed 11-28-2016 as an emergency; operative
6. Certificate of Compliance as to 11-28-2016 order transmitted to OAL 5-16-2017 and filed 6-27-2017 (Register 2017, No. 26).
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.